Sanuwave Health, Inc. SNWV 深 沪
已收盘 08-01 16:00:00 美东时间
36.24
-2.230
-5.80%
华盛通- 最 高38.51
- 今 开38.51
- 成交量 4.96万股
- 最 低 35.49
- 昨 收 38.47
- 总市值 3.11亿
- 52周最高 39.83
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 24.80
- 委 比 81.46%
- 总股本 856.93万
- 历史最高 39.83
- 量 比 1.32
- 振 幅 7.85%
- 历史最低 24.80
- 每 手 1
- 风险率
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Sanuwave Health Finalizes Separation with Former Officer
Sanuwave Health ( ($SNWV) ) just unveiled an update. On May 30, 2025, Sanuwave ...
08-01 05:13
美股大行评级 | 潜在涨幅36%！花旗上调Coinbase目标价升至505美元；摩根大通维持迪士尼"超配"评级，目标价升至138美元
今日重点评级关注：花旗：维持Apellis Pharmaceuticals"买入"评级，目标价从41美元升至46美元；杰富瑞：维持Kiniksa Pharmaceuticals"买入"评级，目标价从45美元升至54美元
07-30 09:36
Roth Capital Initiates Coverage On SANUWAVE Health with Buy Rating, Announces Price Target of $49
Roth Capital analyst Kyle Bauser initiates coverage on SANUWAVE Health (NASDAQ:SNWV) with a Buy rating and announces Price Target of $49.
07-30 00:52
Sanuwave Health to Present at Canaccord Genuity Growth Conference
Sanuwave Health, Inc. announced that its CEO, Morgan Frank, will present at the 45th Annual Canaccord Genuity Growth Conference in Boston on August 12–13, 2025. The presentation is scheduled for August 13, from 9:30 to 9:55 a.m. ET. Mr. Frank will also be available for one-on-one investor meetings during the conference. Sanuwave focuses on developing non-invasive, FDA-approved wound care products aimed at promoting tissue repair and regeneration.
07-22 20:05
Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)
Sanuwave Health, Inc. reported preliminary Q2 2025 revenues of $10.1 million to $10.2 million, a 41-42% increase compared to Q2 2024 and a 50-51% rise in H1 2025 versus H1 2024. CEO Morgan Frank highlighted the completion of a transition period with新增 key leadership and expanded sales teams, covering all national territories. The company expects to release full Q2 results by August 8, 2025.
07-14 20:30
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
Sanuwave Health Inc. appoints Dustin Libby as EVP of commercial operations. With over 20 years of experience in medical device commercial growth and product launches, Libby joins the company to drive scale and agility. He previously scaled a $15M surgical business to over $500M at Abiomed. Sanuwave offers innovative, non-invasive wound care solutions, and Libby aims to leverage his expertise to expand their market leadership.
06-03 11:30
Sanuwave Health Selected for Inclusion in Russell 2000 Index
EDEN PRAIRIE, Minn., May 28, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (NA...
05-29 04:10
Sanuwave Health Selected for Inclusion in Russell 2000® Index
Sanuwave Health, Inc., a leader in non-invasive wound care solutions, announced its inclusion in the Russell 2000®, Russell 3000®, and Russell Microcap® indexes effective June 30, 2025. The Russell indexes, maintained by FTSE Russell, include the 4,000 largest U.S. stocks and are widely used by investors. Sanuwave focuses on developing regenerative medical systems for skin, musculoskeletal tissue, and vascular repair. The company also cautioned a...
05-28 20:10
Sanuwave Health Appoints Greg Bazar to Board of Directors
Greg Bazar, with extensive experience in engineering, technology, and cybersecurity, has joined Sanuwave Health's Board of Directors. Bazar, founder and former chairman of Simpatico Systems and 3D-P, brings a proven track record of leadership and culture-building. Sanuwave CEO Morgan Frank highlighted Bazar’s unique interdisciplinary expertise as crucial for the company’s future. Meanwhile, long-time board member Michael Stolarski is stepping dow...
05-28 20:05
Sanuwave health targets 40%-50% Q2 revenue growth with strategic customer focus
Earnings Call Insights: SANUWAVE Health (SNWV) Q1 2025 Management View CEO Morgan Frank highlighted a strong start to 2025, achieving 61% year-over-year revenue growth in Q1, with revenues reaching $9...
05-10 09:54
